UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Increased CD69+CCR7+ circulating activated T cells and STAT3 expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials

Lupus, 2022-04, Vol.31 (4), p.472-481

2022

Volltextzugriff (PDF)

Correction to: Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo efects of LenabasumTM

Arthritis research & therapy, 2022-03, Vol.24 (1), p.69-69, Article 69

2022

Volltextzugriff (PDF)

Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of LenabasumTM

Arthritis research & therapy, 2022-01, Vol.24 (1), p.1-12, Article 12

2022

Volltextzugriff (PDF)

Increased Myeloid Dendritic Cells and TNF-α Expression Predicts Poor Response to Hydroxychloroquine in Cutaneous Lupus Erythematosus

Journal of investigative dermatology, 2019-02, Vol.139 (2), p.324-332

2019

Volltextzugriff (PDF)

Polymorphisms and serum level of mannose-binding lectin: an Iranian survey

Iranian journal of allergy, asthma, and immunology, 2014-12, Vol.13 (6), p.428-432

2014

Volltextzugriff (PDF)

The effects of immunostimulatory herbal supplements on autoimmune skin diseases

Journal of the American Academy of Dermatology, 2021-04, Vol.84 (4), p.1051-1058

2021

Volltextzugriff (PDF)

Acute onset/flares of dermatomyositis following ingestion of IsaLean herbal supplement: Clinical and immunostimulatory findings

Journal of the American Academy of Dermatology, 2019-03, Vol.80 (3), p.801-804

2019

Volltextzugriff (PDF)

Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial

Journal of investigative dermatology, 2022-10, Vol.142 (10), p.2651-2659.e1

2022

Volltextzugriff (PDF)

Cannabinoid Reduces Inflammatory Cytokines, Tumor Necrosis Factor-α, and Type I Interferons in Dermatomyositis In Vitro

Journal of investigative dermatology, 2017-11, Vol.137 (11), p.2445-2447

2017

Volltextzugriff (PDF)

Recent Advances in Pharmacological Treatments of Adult Dermatomyositis

Current rheumatology reports, 2019-10, Vol.21 (10), p.53-53, Article 53

2019

Volltextzugriff (PDF)

Increased MxA protein expression and dendritic cells in spongiotic dermatitis differentiates dermatomyositis from eczema in a single‐center case‐control study

Journal of cutaneous pathology, 2021-03, Vol.48 (3), p.364-373

2021

Volltextzugriff (PDF)

Myeloid dendritic cells are major producers of interferon-β in dermatomyositis and may contribute to hydroxychloroquine refractoriness

Journal of investigative dermatology, 2021-03, Vol.141 (8), p.1906-1914.e2

2021

Volltextzugriff (PDF)

Self-Education Criteria based on the Educational Thought of Islam

International journal of multicultural and multireligious understanding, 2020-03, Vol.7 (2), p.124

2020

Volltextzugriff (PDF)

Quinacrine Suppresses Tumor Necrosis Factor-α and IFN-α in Dermatomyositis and Cutaneous Lupus Erythematosus

The Journal of investigative dermatology symposium proceedings, 2017-10, Vol.18 (2), p.S57-S63

2017

Volltextzugriff (PDF)

Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Dermatomyositis Patients with Refractory Skin: Disease A Randomized Clinical Trial

Journal of investigative dermatology, 2022-04, Vol.142 (10), p.2651-2659.e1

2022

Volltextzugriff (PDF)

Correction to: Cannabinoid type 2 receptor and in vivo efects of LenabasumTM

Arthritis research & therapy, 2022-03, Vol.24 (1)

2022

Volltextzugriff (PDF)

Sebaceous induction in dermatofibroma: a common feature of dermatofibromas on the shoulder

Journal of cutaneous pathology, 2015-06, Vol.42 (6), p.400-405

2015

Volltextzugriff (PDF)

Cannabinoid type 2 receptor and in vivo effects of LenabasumTM

Arthritis research & therapy, 2022-01, Vol.24 (1)

2022

Volltextzugriff (PDF)

Selective immunoglobulin A deficiency in Iranian blood donors: prevalence, laboratory and clinical findings

Iranian journal of allergy, asthma, and immunology, 2008-09, Vol.7 (3), p.157-162

2008

Volltextzugriff (PDF)

AB003. Increased CD69+ tissue-resident memory T cells and STAT3 expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials

Annals of translational medicine, 2021-03, Vol.9 (5), p.AB003-AB003

2021

Volltextzugriff (PDF)

AB003. Increased myeloid dendritic cells and TNF-α expression predicts poor response to hydroxycoloquine in cutaneous lupus erythematosus

Annals of translational medicine, 2019-08, Vol.7 (S4), p.AB003-AB003

2019

Volltextzugriff (PDF)

AB018. Myeloid dendritic cells (mDCs) are major producers of interferon-beta in dermatomyositis and increased numbers of mDCs are found in hydroxychloroquine nonresponders

Annals of translational medicine, 2021-03, Vol.9 (5), p.AB018-AB018

2021

Volltextzugriff (PDF)

Correction to: Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo efects of Lenabasum TM

Arthritis research & therapy, 2022-03, Vol.24 (1), p.69

2022

Volltextzugriff (PDF)

Determination of lymphocyte subsets reference values in healthy Iranian men by a single platform flow cytometric method

Cytometry. Part A, 2015-03, Vol.87 (3), p.281-281

2015

Volltextzugriff (PDF)

Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of Lenabasum TM

Arthritis research & therapy, 2022-01, Vol.24 (1), p.12

2022

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(28)

Sprache

Englisch
(28)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(13)
Science & Technology
(13)
Humans
(12)
Adult
(6)
Dermatology
(6)
Male
(6)
Dendritic Cells
(5)
Female
(5)
Middle Aged
(5)
Dermatomyositis
(4)
Biopsy
(3)
Dronabinol - Analogs & Derivatives
(3)
Iran
(3)
Treatment Outcome
(3)
Tumor Necrosis Factor-Alpha - Metabolism
(3)
Abstract On Rheumatologic Skin Disease
(2)
Adolescent
(2)
Allergy
(2)
Antimalarials - Pharmacology
(2)
Antimalarials - Therapeutic Use
(2)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Increased CD69+CCR7+ circulating activated T cells and STAT3 expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials

Correction to: Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo efects of LenabasumTM

Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of LenabasumTM

Increased Myeloid Dendritic Cells and TNF-α Expression Predicts Poor Response to Hydroxychloroquine in Cutaneous Lupus Erythematosus

Polymorphisms and serum level of mannose-binding lectin: an Iranian survey

The effects of immunostimulatory herbal supplements on autoimmune skin diseases

Acute onset/flares of dermatomyositis following ingestion of IsaLean herbal supplement: Clinical and immunostimulatory findings

Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial

Cannabinoid Reduces Inflammatory Cytokines, Tumor Necrosis Factor-α, and Type I Interferons in Dermatomyositis In Vitro

Recent Advances in Pharmacological Treatments of Adult Dermatomyositis

Increased MxA protein expression and dendritic cells in spongiotic dermatitis differentiates dermatomyositis from eczema in a single‐center case‐control study

Myeloid dendritic cells are major producers of interferon-β in dermatomyositis and may contribute to hydroxychloroquine refractoriness

Self-Education Criteria based on the Educational Thought of Islam

Quinacrine Suppresses Tumor Necrosis Factor-α and IFN-α in Dermatomyositis and Cutaneous Lupus Erythematosus

Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Dermatomyositis Patients with Refractory Skin: Disease A Randomized Clinical Trial

Correction to: Cannabinoid type 2 receptor and in vivo efects of LenabasumTM

Sebaceous induction in dermatofibroma: a common feature of dermatofibromas on the shoulder

Cannabinoid type 2 receptor and in vivo effects of LenabasumTM

Selective immunoglobulin A deficiency in Iranian blood donors: prevalence, laboratory and clinical findings

AB003. Increased CD69+ tissue-resident memory T cells and STAT3 expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials

AB003. Increased myeloid dendritic cells and TNF-α expression predicts poor response to hydroxycoloquine in cutaneous lupus erythematosus

AB018. Myeloid dendritic cells (mDCs) are major producers of interferon-beta in dermatomyositis and increased numbers of mDCs are found in hydroxychloroquine nonresponders

Correction to: Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo efects of Lenabasum TM

Determination of lymphocyte subsets reference values in healthy Iranian men by a single platform flow cytometric method

Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of Lenabasum TM

Suchergebnisse filtern